Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Shire Expected to Initiate Phase 3 Trial of CINRYZE (SHP616) to Treat Children with Angioedema Attacks in mid-2016

Source Link:: https://www.clinicaltrials.gov/ct2/show/NCT02052141?term=SHP616&rank=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

SHPG

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Shire is currently enrolling patients in a Phase 3 study for CINRYZE (SHP616) for the treatment of children (6-11 years) for the prevention of angioedema attacks. The enrollment is expected to complete and treatment of the trial in mid-2016.

https://www.clinical...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 10, 2016

Occurred Source:

http://investors.shire.com/~/media/Files/S/Shire-IR/annual-interim-reports/year-2016/UKLA-half-yearly-report-2016-final-2016-08-05.pdf

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Cinryze, Shp616, Angioedema Attack Frequency